Profile data is unavailable for this security.
About the company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
- Revenue in USD (TTM)0.00
- Net income in USD-27.16m
- Incorporated2016
- Employees7.00
- LocationTranscode Therapeutics Inc6 Liberty Square, #2382BOSTON 02109United StatesUSA
- Phone+1 (857) 301-6857
- Fax+1 (302) 655-5049
- Websitehttps://www.transcodetherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | RNAZ:NAQ since announced | Transaction value |
|---|---|---|
| Polynoma LLC | -24.63% | -- |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.65m | 12.00 | -- | 0.3187 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.75m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.29m | -10.87m | 8.05m | 16.00 | -- | 1.26 | -- | 2.45 | -17.27 | -17.27 | 5.09 | 3.98 | 0.3025 | 2.74 | 5.08 | 205,752.50 | -100.21 | -73.55 | -191.77 | -123.30 | 43.08 | -- | -331.26 | -476.22 | 0.7618 | -- | 0.0392 | -- | -1.90 | 74.49 | -4.06 | -- | -- | -- |
| StimCell Enegetics Inc | 0.00 | -935.22k | 8.09m | 0.00 | -- | -- | -- | -- | -0.0461 | -0.0461 | 0.00 | -0.0738 | 0.00 | -- | -- | -- | -2,062.23 | -844.03 | -- | -- | -- | -- | -- | -18,037.46 | -- | -17.22 | -- | -- | -- | -- | -297.42 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 8.12m | -- | -- | 0.5679 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Hi-Great Group Holding Co | 48.03k | -64.27k | 8.21m | -- | -- | -- | -- | 170.94 | -0.0006 | -0.0006 | 0.0005 | -0.002 | 0.7229 | 0.5559 | -- | -- | -96.73 | -21.81 | -- | -256.35 | 38.77 | 45.63 | -133.81 | -21.02 | 0.0288 | -- | -- | -- | -36.79 | -- | 60.07 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -27.16m | 8.45m | 7.00 | -- | 5.38 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.19m | 8.52m | 17.00 | -- | 2.28 | -- | -- | -1.35 | -1.35 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -82.86 | -103.16 | -99.57 | -123.95 | -- | -- | -- | -- | -- | -138.68 | 0.00 | -- | -- | -- | -16.46 | -- | -- | -- |
| Bioatla Inc | 0.00 | -64.71m | 8.86m | 61.00 | -- | -- | -- | -- | -1.15 | -1.15 | 0.00 | -0.5313 | 0.00 | -- | -- | 0.00 | -165.61 | -49.22 | -317.99 | -57.35 | -- | -- | -- | -3,690.17 | -- | -- | -- | -- | -- | 16.17 | 43.48 | -- | -- | -- |
| Pulmatrix Inc | 3.00k | -6.22m | 8.89m | 2.00 | -- | 1.88 | -- | 2,964.44 | -1.70 | -1.70 | 0.0008 | 1.30 | 0.0004 | -- | -- | 1,500.00 | -75.43 | -42.08 | -79.47 | -49.93 | -- | -- | -207,333.30 | -210.36 | -- | -- | 0.00 | -- | 6.96 | -0.2644 | 32.31 | -- | 46.99 | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 9.29m | 16.00 | -- | 0.8276 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Transcode Therapeutics Inc's reporting currency: US Dollar USD
4.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2025 | 41.60k | 4.54% |
| UBS Securities LLCas of 31 Dec 2025 | 2.96k | 0.32% |
| Tower Research Capital LLCas of 30 Sep 2025 | 142.00 | 0.02% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 10.00 | 0.00% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 8.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 7.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 3.00 | 0.00% |
| BofA Securities, Inc.as of 30 Sep 2025 | 1.00 | 0.00% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 0.00 | 0.00% |
| DRW Securities LLCas of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
